Fate Therapeutics to Present at Upcoming Investor Conferences
September 01 2017 - 8:00AM
Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company
dedicated to the development of programmed cellular immunotherapies
for cancer and immune disorders, today announced that Scott
Wolchko, President and Chief Executive Officer, will be presenting
at three upcoming investor conferences in September:
- 2017 Wells Fargo Healthcare Conference at 8:15
a.m. ET on Thursday, September 7, 2017 in Boston, MA.
- Cantor Fitzgerald Global Healthcare
Conference at 10:20 a.m. ET on Tuesday, September 26,
2017 in New York, NY.
- Leerink Partners Roundtable Series: Rare Disease &
Immuno-Oncology at 10:00 a.m. ET on Thursday, September
28, 2017 in New York, NY.
Live webcasts of the presentations will be available through the
investor relations section of the Company's website
at www.fatetherapeutics.com. Following the live webcasts,
archived replays of each presentation will be available on the
Company's website for 30 days after the respective
conference.
About Fate Therapeutics, Inc. Fate Therapeutics
is a clinical-stage biopharmaceutical company dedicated to the
development of programmed cellular immunotherapies for cancer and
immune disorders. The Company's hematopoietic cell therapy pipeline
is comprised of NK- and T-cell immuno-oncology programs, including
off-the-shelf product candidates derived from engineered induced
pluripotent cell lines, and immuno-regulatory programs, including
product candidates to prevent life-threatening complications in
patients undergoing hematopoietic cell transplantation and to
promote immune tolerance in patients with autoimmune disease. Its
adoptive cell therapy programs are based on the Company's
novel ex vivo cell programming approach, which it applies
to modulate the therapeutic function and direct the fate of immune
cells. Fate Therapeutics is headquartered in San Diego, CA. For
more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Apr 2023 to Apr 2024